Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SLC13A5 | Q86YT5 | 3/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31509769 | 0.91 | TRPV1 (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL30270924 | 0.85 | CHRM2 (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL21121829 | 0.84 | TSHR (0.40) | MAPK1POLBKDM4EMAPT | |
| SCHEMBL30393112 | 0.83 | PKM (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25683931 | 0.83 | PKM (0.32) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL21122067 | 0.77 | BACE1 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL23692294 | 0.76 | TACR1 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31509913 | 0.76 | TRPV1 (0.31) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL23671698 | 0.75 | ADORA2A (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL21121863 | 0.74 | KDM4E (0.41) | MAPK1TRPV1KDM4ECYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023102239-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | CHRM2 2732/4885CHRM4 991/4885CHRM5 1529/4885 |
| US-11787825-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | CHRM2 4598/4885CHRM4 4325/4885CHRM5 4107/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | CHRM2 789/4885CHRM4 489/4885CHRM5 408/4885 |
| US-20230203069-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | HAVCR2, MAVS, CD4 | CHRM2 4598/4885CHRM4 4325/4885CHRM5 4107/4885 |
| US-20240132527-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | CHRM2 4705/4885CHRM4 4347/4885CHRM5 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.